Hansoh Pharmaceutical | Sustainability & Chart

KYG549581067

Basic information on Hansoh Pharmaceutical

Location: Cayman Islands

Industry: Manufacturing

Website

Impact Score

Description Hansoh Pharmaceutical

Hansoh Pharmaceutical Group is a Chinese pharmaceutical company focused on the research, development, manufacturing, and marketing of pharmaceutical products for chronic diseases and other medical areas.

Hansoh Pharmaceutical Sustainability Performance

Climate

27%

Renewable Energy

Hansoh Pharmaceutical obtains 1,7% of its energy from renewable energies. Target value per method: min. 100%

Greenhouse Gas Emissions

Hansoh Pharmaceutical emits 2,4 times its CO₂ budget of 45,429 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Supply Chain

Taking into account the entire supply chain, Hansoh Pharmaceutical emits 4,5 times its CO₂ budget of 45,429 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Recycling and Recovery of Waste

Hansoh Pharmaceutical recycles 30,8% of its waste. Target value per method: min. 75%

Society

83%

Union Formation and Collective Bargaining Power

Hansoh Pharmaceutical issues 99% collective agreements. Target value per method: min. 80%

CEO Pay Ratio

CEO Zhong Huijuan earns 33 times the average salary of employees. Target value per method: max. 20 times

Employee Turnover Rate

Hansoh Pharmaceutical has an employee turnover rate of 14,4%. Target value per method: max. 10%

Harassment and Discrimination at the Workplace

Hansoh Pharmaceutical meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria

Gender

94%

Women on Board

Hansoh Pharmaceutical has 42,9% women across its top leadership and supervisory bodies. Target value per method: min. 40%

Gender Pay Gap

Hansoh Pharmaceutical has a gender pay gap of 3,9%. Target value per method: max. 3%

Women in Management

Hansoh Pharmaceutical employs 45,9% female managers. Target value per method: min. 40%

Glass Ceiling

The proportion of women in senior management at Hansoh Pharmaceutical is 109,3% of the proportion of women in the overall workforce. Target value per method: min. 90%

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

Renewable Energy

Greenhouse Gas Emissions

Supply Chain

Waste Recycling

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

Compare Hansoh Pharmaceutical with ...

Hansoh Pharmaceutical

?

Impact Score

Climate

Society

Gender

27%

83%

94%

Hansoh Pharmaceutical

?

Impact Score

Climate

Society

Gender

Sources of sustainability performance

Metric	Value	Unit	Year	PDF Name	PDF Page
CEO Pay Ratio
Total wages paid	3 421 675	RMB’000	2025	ANNUAL+REPORT+2025.pdf	124
Number of employees	9 347	people	2025	d42114482de94680bf7f8b7b801daf75.pdf	148
CEO salary	12 007	RMB’000	2025	ANNUAL+REPORT+2025.pdf	126
CEO name	Zhong Huijuan		2025	ANNUAL+REPORT+2025.pdf	33
Employee Turnover Rate
Employee turnover	14,4	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	169
Gender Pay Gap
Unadjusted gender pay gap	3,9	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	172
Glass Ceiling
Women in management	45,9	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	172
Women in workforce	42	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	149
Greenhouse Gas Emissions
Number of employees	9 347	people	2025	d42114482de94680bf7f8b7b801daf75.pdf	148
Scope 1 emissions	11 833,89	tCO2e	2025	d42114482de94680bf7f8b7b801daf75.pdf	69
Scope 2 emissions, location based	97 828,71	tCO2e	2025	d42114482de94680bf7f8b7b801daf75.pdf	69
Harassment and Discrimination at the Workplace
Confidentiality mechanisms	Yes		2025	d42114482de94680bf7f8b7b801daf75.pdf	51
Incident notification mechanism	Yes		2025	d42114482de94680bf7f8b7b801daf75.pdf	51
Retaliation safeguards	Yes		2025	d42114482de94680bf7f8b7b801daf75.pdf	146
Anti-discrimination policy	Yes		2025	d42114482de94680bf7f8b7b801daf75.pdf	140
Renewable Energy
Total renewable energy consumption	3 451,45	MWh	2025	d42114482de94680bf7f8b7b801daf75.pdf	167
Total energy consumption	25 091,31	TCE	2025	d42114482de94680bf7f8b7b801daf75.pdf	167
Supply Chain
Number of employees	9 347	people	2025	d42114482de94680bf7f8b7b801daf75.pdf	148
Scope 3 emissions	93 115,14	tCO2e	2025	d42114482de94680bf7f8b7b801daf75.pdf	69
Scope 1 emissions	11 833,89	tCO2e	2025	d42114482de94680bf7f8b7b801daf75.pdf	69
Scope 2 emissions, location based	97 828,71	tCO2e	2025	d42114482de94680bf7f8b7b801daf75.pdf	69
Union Formation and Collective Bargaining Power
Collective bargaining agreements coverage	99	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	172
Recycling and Recovery of Waste
Waste recycled	30,81	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	168
Women on Board
Women on supervisory board	3	people	2025	ANNUAL+REPORT+2025.pdf	33
Supervisory board size	7	people	2025	ANNUAL+REPORT+2025.pdf	33
Women in Management
Women in management	45,9	%	2025	d42114482de94680bf7f8b7b801daf75.pdf	172

Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

Find more sustainable companies

Home Find Companies & ETFs Learn to invest Academy Glossary Our Method

Imprint Privacy Policy GTCContact UsESG Rating Disclosure

© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev